Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII)
Study demonstrates TB-402 superior antithrombotic activity to enoxaparin
12-Jul-2010 -
ThromboGenics NV and co-development partner BioInvent International announced that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis (ICT) in Milan, Italy. TB-402 is a long acting anticoagulant that ...
Belgium
Italy
reductions
+5